Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Tadakazu Hisamatsu et al.|The Lancet|2022Cited by 383
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b studySéverine Vermeire, Bruce E. Sands, Josianne Nitcheu et al.|Journal of Crohn s and Colitis|2025Cited by 10
130 Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)Bruce E. Sands, Séverine Vermeire, Silvio Danese et al.|The American Journal of Gastroenterology|2025Cited by 1